

# ABRAHAM CHACHOUA, M.D.

November 2011

## I. EDUCATION AND PROFESSIONAL EXPERIENCE

### A. Educational Background

1978                      *Medical Doctorate*                      (M.D.)  
Monash University, Melbourne, Australia  
Graduated with Honors

### B. Professional Positions and Appointments

#### *Professional Appointments*

**2011 – Present**                      *Interim Director*  
Division of Hematology and Medical Oncology  
New York University Medical Center, New York, NY

2010 – Present                      *Jay and Isabel Fine Associate Professor of Oncology*  
Division of Hematology and Medical Oncology  
New York University Medical Center, New York, NY

2002-Present                      *Associate Professor of Medicine*  
New York University Medical Center, New York, NY

2002-Present                      *Associate Professor*  
Department of Urology  
New York University Medical Center, New York, NY

1998-2002                      *Assistant Professor*  
Department of Urology  
New York University Medical Center, New York, NY

1995-1997                      *Director, Oncology, Section of Hematology/Oncology*  
Brooklyn Hospital Center, Brooklyn, NY

1990-2002                      *Assistant Professor of Clinical Medicine*  
New York University Medical Center, New York, NY

1988-1990                      *Research Assistant Professor*  
New York University Medical Center, New York, NY

1985-1988                      Teaching Assistant  
New York University Medical Center, New York, NY

#### *Postdoctoral Training*

1984 -1985                      *Clinical Fellow*  
Hematology/Oncology  
Peter MacCallum Hospital, Melbourne, Australia

1983-1984                      *Clinical Fellow*



**Title: 9 Cis-Retinoic Acid and Interferon- $\alpha$  in Kaposi's Sarcoma**

Evaluated the efficacy of 9-cis-retinoic acid combined with interferon-1 as novel treatment for HIV associated Kaposi's sarcoma.

**Grant: NCI (1 U01CA70075)                      9/30/95 - 7/31/99**

**Role: Co-Investigator / Friedman-Kien (PI)**

**Title: NYUMC - AIDS-Related Malignancy Consortium**

Developed and executed multicenter Phase I and II clinical treatment trials using novel agents and/or innovative approaches for the treatment of patients with AIDS-associated malignancies and to expand and maintain the established, centralized tissue storage bank containing well characterized patient specimen.

**Grant: NCI (1 U01 CA5826)                      9/30/92 - 9/29/96**

**Role: Chachoua (PI)**

**Title: Evaluations of Cytokine and Chemotherapy Combinations**

Clinical Trials Program: Implement Phase I clinical trials of combinations of IL-1 alpha and high dose cisplatinium in patients with melanoma; Laboratory Program: Measured the effects of treatment on specific tumor and host cell functions that will help to reveal mechanisms of response or resistance to the therapeutic protocol.

### III. Bibliography

#### A. Publications

1. **Chachoua A**, Green M, Muggia F. Immune modulating therapy in gastrointestinal cancer. *Am J Gastroenterol* 1986; Vol. 81(8):623-628.
2. **Chachoua A**. Current Aspects on Biological Response Modifiers. *Cancer Treatment Update* 1986; Vol. V1(3):2-4, May-June, 1986.
3. Green MD, **Chachoua A**. Bladder Cancer. *Mediguide to Oncology*. Vol. 6(4):1-6, 1986.
4. **Chachoua A**, Oratz R, Green MD, Muggia FM. Acquired Immune Deficiency Syndrome. In: *Cancer Chemotherapy Annual*. HM Pinedo, BA Chabner (Eds). Elsevier Science Publishers, The Netherlands. *Cancer Chemother.* 8:305-332, 1986.
5. **Chachoua A**. Adjuvant chemotherapy of bladder cancer. In: *Cancer Treat Update*. Vol VI (5), 3-5, 1986.
6. **Chachoua A**, Green MD. New Antiviral Compounds and Impact in Management of Neoplastic Diseases and AIDS. *Cancer Treat Res.* 36:205-232, 1987.
7. **Chachoua A**, Oratz R, Green MD, Muggia FM. Acquired Immune Deficiency Syndrome. In: *Immunology of Malignant Disease*. R Baldwin (Ed). MTP Press. pp 225-261, 1987.
8. Chaudhry AP, **Chachoua A**, Saltzman BR, Friedman-Kien AE. AIDS-associated Kaposi's sarcoma. Letter to Editor. *J Am Dent Assoc.* 115:824, 826, 1987.
9. **Chachoua A**, Green MD, Laubenstein L, Wernz J, Muggia FM. Phase II Study of oral idarubicin in patients with AIDS-associated Kaposi's sarcoma. *Cancer Treat Rep.* 71:775-776, 1987.
10. **Chachoua A**, Dieterich D, Krasinski K, Greene J, Laubenstein L, Wernz J, Buhles W, Koretz S. 9-(1,3-dihydroxy-2-propoxymethyl) guanine (Ganciclovir) in the treatment of cytomegalovirus gastrointestinal disease with the acquired immunodeficiency syndrome. *Ann Int Med.* 107(2):133-137, 1987.
11. Chaudhry AP, **Chachoua A**, Saltzman BR, Friedman-Kien A. AIDS and occlusal trauma. *J Am Dent Assoc.* 115(5):672, 674, 1987
12. Oratz R, **Chachoua A**, Green MD. Principles of chemotherapy. In: *Chemotherapy Manual*. J Rosenthal (Ed).
13. Oratz R, **Chachoua A**, Speyer J. Intraperitoneal Therapy in Gastrointestinal Malignancies. *Advances in Oncology.* 3(4):23-29, 1987.
14. Chaudhry AP, **Chachoua A**, Saltzman BR, Friedman-Kien A. Oral candidiasis and AIDS. Letter to Editor. *J Am Dent Assoc.* 116(7):818, 820, 1988.
15. **Chachoua A**, Hochster H, Muggia FM. Doxorubicin. In: *Handbook of Chemotherapy in Clinical Oncology*. JP Droz, E Cvitkovic, JP Armand, S Khoury, (Eds). F.I.I.S. Publishers, France. 125-127, 1988.
16. Green MD, **Chachoua A**, Muggia FM, Leichman L. Combined modality treatment of squamous cell carcinoma of the esophagus. In: *Concepts, Clinical Developments, and Therapeutic Advances in Cancer Chemotherapy*. FM Muggia (Ed). Martinus Nijhoff Publishers, Boston, Vol. 4.
17. **Chachoua A**, Beller U. Intraperitoneal Therapy with Biologic Response Modifiers. *Cancer Treat Update*. Vol. III, 1988.

18. Dieterich DT, **Chachoua A**, Lafleur F, Worrell C. Ganciclovir treatment of gastrointestinal infections caused by cytomegalovirus in patients with AIDS. *Rev Infect Dis.* 10:S532-S537, 1988.
19. **Chachoua A**, Dieterich D. 9-(1,3-dihydroxy-2-propoxymethyl) guanine (Ganciclovir) in the Treatment of Cytomegalovirus Gastrointestinal Disease with the Acquired Immunodeficiency Syndrome. *Year Book of Medicine.* 1988.
20. **Chachoua A**, Green MD, Valentine F, Muggia FM. Phase I/II Trial of Thymostimulin in opportunistic infections of the acquired immune deficiency syndrome. *Cancer Invest.* 7(3):225-229, 1989.
21. **Chachoua A**, Green MD, Wernz J, and Muggia F. Phase II Trial of ICRF-187 in Patients with Acquired Immune Deficiency Related Kaposi's Sarcoma (AIDS-KS). *Invest New Drugs.* 7:327-331, 1989.
22. Walsh C, Speyer J, Wernz J, Hochster H, Grossberg H, **Chachoua A**, Molinaro P, Meyers M, Blum R. Phase I Study of the Combination of Alpha-2-Interferon and Cisplatinum. *J Biol Response Mod.* 8(1):11-15, 1989.
23. **Chachoua A**, Krigel R, Lafleur F, Ostreicher R, Speer M, Laubenstein L, Wernz J, Rubenstein P, Zang E, Friedman-Kien A. Prognostic Factors and Staging Classification of Patients with Epidemic Kaposi's Sarcoma. *J Clin Oncol.* 7(6):774-780, 1989.
24. Beller U, **Chachoua A**, Speyer J, Sorich J, Dugan M, Liebes L, Hayes R, Beckman M. Phase Ib Study of Low Dose Intraperitoneal recombinant interleukin-2 in patients with refractory advanced ovarian cancer: rationale and preliminary report. *Gynecol Oncol.* 34:407-412, 1989.
25. Liebes L, Walsh C, **Chachoua A**, Oratz R, Richards D, Hochster H, Peace D, Alba S, Le Sher D, Blum R, and Vilcek J. Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma. *J Natl Cancer Inst.* 84(9):694-9, 1992.
26. Cho J, **Chachoua A**. Kaposi's sarcoma. *Curr Opin Oncol.* 4(4):667-73, 1992.
27. Muggia FM, **Chachoua A**, Hochster H. Doxorubicin. In: *Handbook of Chemotherapy in Clinical Oncology.* E Cvitkovic, JP Droz, JP Armand, S Khoury (Eds). Scientific International Ltd. pp. 277-280, 1993.
28. **Chachoua A**, Oratz R, Hoogmoed R, Caron D, Peace D, Liebes L, Blum RH, and Vilcek J. Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factor. *J Immunother Emphasis Tumor Immunol.* 15(3):217-224, 1994.
29. **Chachoua A**, Oratz R, Liebes L, Alter RS, Felice A, Peace D, Vilcek J, and Blum RH. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma. *J Immunother Emphasis Tumor Immunol.* 16(2):132-141, 1994.
30. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, **Chachoua A**, Raphael B, Vinci RZ, and Blum RH. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. *J Clin Oncol.* 12:553-559, 1994.
31. Gollub MJ, Bosniak MA, Schlossberg P, **Chachoua A**. Extension of a secondary adrenal neoplasm into the inferior vena cava. *Abdom Imaging.* 19(4):359-60, 1994.
32. Katyal S, Kramer EL, Noz ME, McCauley D, **Chachoua A**, Steinfeld A. Fusion of immunoscintigraphy SPECT with CT of the chest in patients with non small cell lung cancer. *Cancer Res (suppl).* 5759s-5763s, 1995.
33. Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H, **Chachoua A**, Wernz J, Zeleniuch-Jacquotte A, Blum R, and Speyer J. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: An Active regimen with limiting neurotoxicity. *J Clin Oncol.* 14:1993-1999, 1996.

34. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, **Chachoua A**, Blum R, Zeleniuch-Jacquotte A. Effect of Prolonged Topotecan Infusion on Topoisomerase I Levels: A Phase I and Pharmacodynamic Study. *Clin Can Res.* Vol. 8 1245-1252, 1997.
35. Gottlieb JJ, Washenik K, **Chachoua A**, Friedman-Kien A. Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin. *Lancet.* 350(9088):1363-4, 1997.
36. Rosenthal MA, Dennis D, Liebes L, Furmanski P, Caron D, Garrison L, Wiprovnick J, Peace D, Oratz R, Speyer J, and **Chachoua A**. Biologic activity of Interleukin 1 (IL-1) alpha in patients with refractory malignancies. *J Immunother.* 21(5):371-378, 1998.
37. Yan Z, Hummel P, Waisman J, Newstead GM, **Chachoua A**, Chhieng D, Cohen JM, Cangiarella J. Prostatic adenocarcinoma metastatic to the breasts: report of a case with diagnosis by fine needle aspiration biopsy. *Urology.* 55(4):590, 2000.
38. Ferrari AC, **Chachoua A**, Singh H, Rosenthal M, Taneja S, Bednar M, Mandeli J, Muggia F. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma. *Cancer.* 91(11):2039-45, 2001.
39. Ko YJ, Small EJ, Kabbinavar F, **Chachoua A**, Taneja S, Reese D, DePaoli A, Hannah A, Balk SP, Bubley GJ. A multi-institutional Phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. *Clin Cancer Res.* 7(4):800-5, 2001.
40. Yang GC, Yee HT, Wu CD, Aye LM, **Chachoua A**. TIA-1+ cytotoxic large T-cell lymphoma of the mediastinum: case report. *Diagn Cytopathol.* 26(3):154-7, 2002.
41. Hochster H, **Chachoua A**, Speyer J, Escalon J, Zeleniuch-Jacquotte A, Muggia F. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. *J Clin Oncol.* 21(14):2703-7, 2003.
42. Sewak S, **Chachoua A**, Hamilton A, Taneja S, Lee J, Utate M, Sorich J, Muggia FM. A Phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting. *Anticancer Drugs.* 14(1):67-72, 2003.
43. Perez-Soler R, **Chachoua A**, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. *J Clin Oncol.* 22(16):3238-47, 2004.
44. Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, **Chachoua A**, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM. Proteasome inhibition with bortezomib (PS-341): a Phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. *J Clin Oncol.* 23(25):6107-16, 2005.
45. Sanfilippo NJ, Taneja SS, **Chachoua A**, Lepor H, Formenti SC. Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer. *J Clin Oncol.* 26(18):2973-8, 2008.
46. Probst S, Seltzer A, **Chachoua A**, Friedman K. Azygos venous tumor thrombus from renal cell carcinoma detected by F-18 FDG PET/CT. *Clin Nucl Med.* 2010 Oct;35(10):832-3.
47. Alpert JB, Nonaka D, **Chachoua A**, Pass HI, Ko JP. Increasing dyspnea due to an anterior mediastinal mass. *Chest.* 2011 Jan;139(1):217-23. No abstract available.

48. Probst S, Seltzer A, Spieler B, **Chachoua A**, Friedman K. The appearance of cardiac metastasis from squamous cell carcinoma of the lung on F-18 FDG PET/CT and post hoc PET/MRI. *Clin Nucl Med*. 2011 Apr;36(4):311-2. No abstract available.
49. Ballas MS, **Chachoua A**. Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. *Oncotargets Ther*. 2011;4:43-58. Epub 2011 May 30.

## B. Abstracts

1. **Chachoua A**, Dieterich D, and Newall J. 9-1, 3 Dihydroxy-2 Propoxymethyl Guanine (DHPG) in Patients with AIDS and CMV Infections. *Proc Am Soc Clin Onc*. 5:84, 1986.
2. Muggia F, **Chachoua A**, Green MD, Wernz JC, Laubenstein L, Krigel R. Oral 4-Demethoxydaunorubicin (DMDR) in Epidemic Kaposi's Sarcoma (EKS). *Proc Am Soc Clin Onc*. 5:136, 1986.
3. Dieterich DT, **Chachoua A**, Faust M, Moses M. Treatment of Cytomegalovirus Gastrointestinal Infections in AIDS Patients with 9-(1,3-Dihydroxy-2-Propoxy-Methyl) Guanine. *Gastroenterology*. 90(5):1395, 1986.
4. Dieterich DT, **Chachoua A**, Faust M. Difluoromethylornithine Treatment of Cryptosporidiosis in AIDS Patients. *Gastroenterology*. 90(5):1395, 1986.
5. **Chachoua A**, Dieterich DT. 9-1, 3 Dihydroxy-2 Propoxymethyl Guanine in Patients with AIDS and CMV Infections. *Clinical Research*. 34(2):514 A, 1986.
6. Laubenstein L, Raphael B, **Chachoua A**, Scholes J, Mouradian J, Metroka C. Clinical Manifestations of B-Cell Hyperplasia in Response to HTLV-III/LAV Infection. *Proc. International Conference on AIDS, Paris, France*. pp. 37, June 23, 24, 25, 1986.
7. Dieterich DT, **Chachoua A**, Greene J, Garay S. Eflornithine Treatment of Resistant Pneumocystis Carinii Pneumonia (PCP) in AIDS Patients. *Proc. International Conference on AIDS, Paris, France*. pp. 53, June 23, 24, 25, 1986.
8. **Chachoua A**, Dieterich DT, Wernz J, Muggia F. CMV infections in patients with AIDS treated with 9-1, 3 Dihydroxy-2 Propoxymethyl guanine. *Proc. International Conference on AIDS, Paris, France*. pp. 6, June 23, 24, 25, 1986.
9. Dieterich DT, Lafleur F, **Chachoua A**, Worrell C. Successful Therapy of Cytomegalovirus (CMV) Infections in Patients (Pts) with Acquired Immunodeficiency Syndrome (AIDS) with Ganciclovir. *III International Conference on Acquired Immunodeficiency Syndrome (AIDS)*. June 1-5, 1987.
10. **Chachoua A**, Green MD, Girman A, Ward C, Wernz J, Muggia FM. ICRF-187 in patients (pts) with AIDS and Kaposi's sarcoma (KS). *Proc Am Soc Clin Onc*. 6:A4, 1987.
11. Hochster H, Liebes L, Dieterich D, **Chachoua A**, Valentine F, Blum R. Pharmacokinetics of azidothymidine (AZT), 9-(1,3-Dihydroxy-2-propoxymethyl) guanine (DHPG), and doxorubicin (dox) combinations in Phase I trials. *European Conference on Clinical Aspects of HIV Infection*. Brussels, Belgium, December 10-11, 1987. Abstract 119.
12. **Chachoua A**, Hochster H, Green M, Ward C, Gutknecht, Chuang-Stein C, Nicholas J, Merritt J. Phase II trial of bropirimine (ABPP) in patients (pts) with AIDS related Kaposi's sarcoma. *Proc Am Soc Clin Onc*. 7:A21, 1988.
13. Green M, **Chachoua A**, Laubenstein L, Ward C, Flanagan S, Fischl M. Randomized study of gamma interferon (IFN) in patients (pts) with AIDS related Kaposi's sarcoma (KS). *Proc Am Soc Clin Onc*. 7:A10, 1988.

14. **Chachoua A**, Lafleur F, Downey A, Wernz J, Hymes K, Laubenstein L, Poiesz A, Friedman-Kein A. Randomized placebo controlled trial of ribavirin in patients (pts) with AIDS-KS and ARC. Proc Am Soc Clin Onc. 7:A9, 1988.
15. Liebes L, Hochster H, **Chachoua A**, Javitt NB. Azidothymidine glucuronidation by HEP-G2 cells. AFCR, 1988.
16. Hochster H, Liebes L, **Chachoua A**, Mendoza S, Wernz J. Phase I study and pharmacokinetics of weekly doxorubicin (DOX) and AZT in Kaposi's sarcoma (KS). IV International Conference on AIDS. June 12-16, 1988. Stockholm, Sweden.
17. **Chachoua A**, Krigel R, Lafleur F, Speer M, Ostriecher R, Laubenstein L, Zang E, Rubenstein P, Friedman-Kien A. Prognostic factors and staging classification of patients with epidemic Kaposi's sarcoma. IV International Conference on AIDS. June 12-16, 1988. Stockholm, Sweden.
18. Beller U, Speyer J, **Chachoua A**, Dugan M, Liebes L, Sorich J, and Beckman EM. Phase Ib study of low-dose intraperitoneal (ip) recombinant interleukin-2 (rIL-2) in patients (pts) with refractory advanced ovarian cancer-preliminary report. Society of Gynecologic Oncologists. February 5-9, 1988.
19. Walsh C, **Chachoua A**, Hochster H, Downey A, Wood D, Nadler P, Speyer J, Wernz J, Oratz R, Meyers M, and Blum RH. Phase I study of recombinant human tumor necrosis factor (rHTNF). Proc Am Soc Clin Onc. 8:753, 1989.
20. Liebes L, **Chachoua A**, Valentine F. Evaluation of soluble T8 receptor in patients with HIV infection. AFCR 1989.
21. Speyer JL, Walsh CM, Downey A, Hochster H, Oratz R, Goldenberg A, **Chachoua A**, and Blum RH. A Phase I trial of escalating doxorubicin (dox) with ICRF-187 for cardioprotection and GM-CSF for bone marrow support. Proc Am Soc Clin Onc. 9:161, 1990.
22. **Chachoua A**, Krigel R, Schiller JH, Wadler S, Kirkwood J, Blum RH. Phase II study of combination interferon beta and gamma in patients with non small cell lung cancer (NSCLC). An ECOG pilot study. Proc Am Soc Clin Onc. 9:936, 1990.
23. Hochster H, Oratz R, Wernz J, Speyer J, Meyers M, **Chachoua A**, Walsh C, Dunleavy S, Blum R, Kreis W, Nadler P, Spigelman MK. Weekly amonafide: Phase I study of a novel schedule. Proc Am Soc Clin Onc. 9:265, 1990.
24. Hoogmoed RP, **Chachoua A**, Dunleavy SE, Liebes LF, Kanganis D, Oratz R, Speyer JL, Wernz JC, Meyers MI, Weissman J, Walsh CM, Hochster HS, Le J, Vilcek J, and Blum RH. Phase IB study of GM-CSF as a monocyte activator in adult cancer patients (pts). Proc Am Soc Clin Onc. 9:747, 1990.
25. Miller RL, **Chachoua A**, Le J, Blum RH, and Vilcek J. Lack of stimulation of human monocyte-mediated cytotoxicity by recombinant macrophage-colony stimulating factor. Proc Amer Assoc Cancer Res. 31:1429, 1990.
26. **Chachoua A**, Kanganis D, Liebes L, Adler A, Blum RH, Le J, Vilcek J. Interleukin 4 down regulates monocyte mediated cytotoxicity against tumor cell targets. Proc Amer Assoc Cancer Res. 31:1430, 1990.
27. Dennis D, **Chachoua A**, Caron D, Garrison L, Liebes L, Furmanski P, Wiprovnick J, Peace D, Oratz R, Speyer J, Blum RH. Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignancies. Proc Am Soc Clin Onc. 11:830, 1992.

28. Felice AJ, **Chachoua A**, Oratz R, Caron D, Peace D, Liebes LF, Hochster HS, Vilcek J, Lafleur F, Blum RH. A Phase Ib trial of GM-CSF with murine monoclonal antibody R24 in patients with metastatic melanoma. *Proc Am Soc Clin Onc.* 11:1188, 1992.
29. Hochster H, Speyer J, Oratz R, Meyers M, Wernz J, **Chachoua A**, Raphael B, Lee R, Sorich J, Taubes B, Liebes L, Fry D, Blum R. Novel schedule for administration of topotecan (TPT): 21 day low dose continuous infusion (CI). Submitted for ECCO meeting in Jerusalem, November 1993.
30. Hochster H, Speyer J, Oratz R, Meyers M, Wernz J, **Chachoua A**, Raphael B, Lee R, Sorich J, Taubes B, Liebes L, Fry D, Blum R. Topotecan 21-day continuous infusion: Excellent tolerance of a novel schedule. *Proc Am Soc Clin Onc.* 12:356, 1993.
31. Schuchter L, Neuberg D, Atkins M, Tester B, Recló A, Sickles C, Moore J, Light B, Anderson T, **Chachoua A**, Dutcher J. A Phase I study of interleukin-1 alpha (IL-1) and high dose cyclophosphamide (Cy) in patients with advanced cancer. *Proc Am Soc Clin Onc.* 13:327, 1994.
32. Wasserheit C, **Chachoua A**, Hochster H, Farrell K, Simpson K, Blum R. Phase I study of edatrexate (Eda) and doxorubicin (dox) in patients with solid tumors. *Proc Am Soc Clin Onc.* 13:1381, 1994.
33. Wasserheit C, Alter R, Speyer J, Hochster H, Oratz R, Wernz J, **Chachoua A**, Meyers M, Sorich J, Downey A, Friedberg A, Blum R. Phase II trial of paclitaxel and cisplatin (DDP) in women with metastatic breast cancer. *Proc Am Soc Clin Onc.* 13:204, 1994.
34. Wasserheit C, **Chachoua A**, Hochster H, Oratz R, Downey A, Farrell K, Simpson K, Blum R. Phase I study of edatrexate, doxorubicin and G-CSF in patients with solid tumors. *Proc Am Soc Clin Onc.* 14:1587, 1995.
35. Frazein A, Wasserheit C, Hochster H, Oratz R, Wernz J, **Chachoua A**, Meyers M, Sorich J, Downey A, Blum R, Speyer J. High rate of peripheral neuropathy may limit paclitaxel and cisplatin combination in women with advanced breast cancer. *Proc Am Soc Clin Onc.* 14:145, 1995.
36. Dosik D, **Chachoua A**, Oratz R, Shapiro R, Speyer J, Wasserheit C, Frazein A, Downey A, Blum R. Phase I study of IL-1a combined with high dose cisplatin (CDDP) in patients (pts) with metastatic melanoma. *Proc Am Soc Clin Onc.* 15:440, 1996.
37. Hochster H, Liebes L, Z-Jacquotte A, Sorich J, Speyer J, Oratz R, **Chachoua A**, Blum R, Taubes B, Ludwig E, Kim A, Fry D, Broom C. Pharmacodynamics of 21-day topotecan infusion in a Phase II study of ovarian cancer: Correlation with TPT administration and heme toxicity. *Proc Am Soc Clin Onc.* 15:476, 1996.
38. Hochster H, Speyer J, Wadler S, Runowicz C, Wallach R, Oratz R, **Chachoua A**, Sorich J, Taubes B, Ludwig E, Broom C, Blum R. Phase II study of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer: A highly active regimen (A NYGOG Study). *Proc Am Soc Clin Onc.* 15:775, 1996.
39. Perez L, Kopel S, San Y, Carinci D, Razia S, Banad A, Nayak A, Grand M, Malhotra H, Celo J, Cheslock E, Fitzgerald D, Feldman A, Daya R, Grinberg M, Abraham N, **Chachoua A**, Cook P. Feasibility of a novel regimen of high dose thiotepa, L-Phenylalanine, and Carboplatin with Autologous Hematopoietic Stem Cell Transplantation in Breast Cancer Patients. *Proc Am Soc Clin Onc.* 15:344, 1996.
40. **Chachoua A**, Sorich J, Wasserheit C, Taubes B, Friedberg A, Arbuck S, and Speyer J. Phase I study of paclitaxel (P) combined with 14-day topotecan (T) continuous IV (CIV) infusion in previously treated and untreated pts. *Proc Am Soc Clin Onc.* 16:839, 1997.
41. Hochster H, Liebes L, Speyer J, Sorich J, **Chachoua A**, Raphael B, Moskovits T, Taubes B, Friedberg A, Buckley M, Fry D, Arbuck S, Blum R and Potmesil M. Phase I and pharmacodynamic study of prolonged infusion 9-amino-camptothecin (9-AC) in two formulations. *Proc Am Soc Clin Onc.* 16:704, 1997.

42. Klein P, Lyass O, Sorich J, Wasserheit C, Hochster H, **Chachoua A**, Speyer JL, Oratz R, Lafair J, Downey A, Kotcher L, Muggia F, Gabizon A. Doxil plus cisplatin: Combined results of two Phase I studies. Proc Am Soc Clin Onc. 17:942, 1998.
43. Taneja S, **Chachoua A**, Ferrari A, Utate M, Kutz L, Stone N, Stock R, Baldwin Y, Lepor H, Muggia F. Phase I trial of taxol/estramustine in patients with hormone refractory prostate cancer. Proc Am Soc Clin Onc. 18:1364, 1999.
44. **Chachoua A**, Hochster H, Steinfeld A, Klein P, Wasserheit C, Sorich J, Downey A, Sarpong A, and Muggia F. Feasibility of seven weeks concomitant topotecan (T) continuous infusion with thoracic radiation. Proc Am Soc Clin Onc. 18:1873, 1999.
45. Hochster H, Rosenthal M, **Chachoua A**, Sorich J, and Muggia F. Prolonged topotecan infusion combined with doxil® - A well tolerated regimen. Proc Am Soc Clin Onc. 18:822, 1999.
46. Klein P, Wasserheit C, Hochster H, **Chachoua A**, Speyer JL, Oratz R, Downey A, Sorich J, Kotcher L, Eisenberg T, Muggia F. Apparent protection of doxil skin and oral toxicities when combined with cisplatin (CDDP): Results of a Phase I study. Proc Am Soc Clin Onc. 18:835, 1999.
47. Ko YJ, **Chachoua A**, Small E, Reese D, Kabbinavar F, Taneja S, DePaoli A, Hannah A, Balk S, Bubley G. Phase II study of SU101 in patients with PSA-positive prostate cancer. Proc Am Soc Clin Onc. 18:1220, 1999.
48. Chap L, **Chachoua A**, Lopez A, DePaoli A, and Hannah A. A Phase II study of SU101 in patients with advanced ovarian cancer. Proc Am Soc Clin Onc. 18:1437, 1999.
49. Hochster HS, **Chachoua A**, Wernz J, Escalon J, Martinez S, Muggia F. Oxaliplatin with weekly bolus 5FU and low-dose leucovorin (LV): Early report of high activity in first line therapy of advanced colorectal cancer (ACRC). Proc Am Soc Clin Onc. 19:1131, 2000.
50. Hamilton A, Hochster H, Rosenthal M, **Chachoua A**, Sorich J, Cahr M, Muggia F. Continuous infusion topotecan (TP-CI) with doxil (DX): A Phase I study of dual topoisomerase inhibition. Proc Am Soc Clin Onc. 19:777, 2000.
51. Singh H, Ferrari AC, Bednar E, **Chachoua A**, Rosenthal M, Muggia F. Weekly paclitaxel and high dose oral estramustine in hormone refractory prostate cancer. Proc Am Soc Clin Onc. 19:1494, 2000.
52. Hochster HS, **Chachoua A**, Speyer J, Wernz J, Pavlick A, Escalon J, Hayek M, Muggia F. First-line activity of oxaliplatin with weekly bolus 5FU and low-dose leucovorin (LV) in advanced colorectal cancer (CRC). Proc Am Soc Clin Onc. 20:138a, abstract #548, 2001.
53. Speyer JL, Hochster H, **Chachoua A**, Farrell K, Cosmidis A, Muggia F. A Phase I/II study of eniluracil/5FU plus oxaliplatin (FOX-E) in patients with pre-treated colorectal cancer (CRC). Proc Am Soc Clin Onc. 20:144a, abstract #547, 2001.
54. Liebes L, Hochster H, Speyer J, **Chachoua A**, Hamilton A, Oratz R, Pavlick A, Sorich J, Francois A, Muggia F. Enhanced myelosuppression of topotecan when combined with the farnesyl transferase inhibitor, R115777: A Phase I & pharmacodynamic study. Proc Am Soc Clin Onc. 20:81a, abstract #321, 2001.
55. Sewak S, **Chachoua A**, Hamilton A, Taneja SS, Lee J, Utate M, Sorich J, Kutz L, Goldberg J, Muggia FM. Pacl-E-Vin: Triple tubulin targeting in a Phase I study of paclitaxel, estramustine phosphate and vinorelbine. Proc Am Soc Clin Onc. 20:2121, 2001.

56. **Chachoua A**, Taneja S, Bettini AC, Cooper J, Ellerin B, Kuber N, Chodkiewicz C, Lepore H, Yee H, DeWyngaert K, Kim M, Formenti SC. Preliminary data on feasibility of a regimen combining bi-weekly paclitaxel and radiation therapy in androgen ablated locally advanced prostate cancer. Proc Am Soc Clin Onc. 20:2404, 2001.
57. Muggia F, Haigentz M, Hochster H, Macapinlac M, Nierodzik ML, Mirchandani D, Volm M, Pavlick A, Sorich J, Lee J, **Chachoua A**, Sewak S, Oratz R, Wernz J, Kim M, Hamilton A. Gemcitabine (G)/Cisplatin (P) with and without amifostine (A): Comparative toxicities. Proc Am Soc Clin Onc. 20:484, 2001.
58. Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero RC, **Chachoua A**, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Wright J, Elliott P, Adams J, Muggia FM. PS-341: Phase I study of a novel proteasome inhibitor with pharmacodynamic endpoints. Proc Am Soc Clin Onc. 20:336, 2001.
59. Perez-Soler R, **Chachoua A**, Huberman M, Karp D, Rigas J, Hammond L, Rowinsky E, Preston G, Ferrante KJ, Allen LF, Nader PI, Bonomi P. A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Onc. 20:1235, 2001.
60. Hochster HS, **Chachoua A**, Speyer J, Escalon J, Grenade N, Zeleniuch-Jacquotte A, Muggia F. Oxaliplatin with weekly bolus 5FU and low-dose leucovorin (bFOL) as first-line therapy of colorectal cancer: a Phase II study. Proc Am Soc Clin Onc. 22:275, abstract #1103, 2003.
61. Jacobson DR, Pei Z, Zhu H, Bogdan C, **Chachoua A**, Perez-Perez GI, Blaser MJ. Helicobacter pylori colonization and lung cancer histology: A possible explanation for the recent rise in the incidence of adenocarcinoma relative to squamous cell carcinoma. Proc Am Soc Clin Onc. 22:666, abstract # 2677, 2003.
62. Kim E, Hochster H, Novik Y, **Chachoua A**, Speyer J, Muggia F. A Phase I study of carboplatin plus oral topotecan in advanced malignancies. Proc Am Soc Clin Onc. 23:161, abstract # 2137, 2004.
63. Chen AL, Ryan T, Muggia F, **Chachoua A**, Escalon J, Moore S, Haniff F, Levinson B, Nicol S, Hochster H. Phase I dose-escalating study of bi-weekly pemetrexed (MTA) with fixed dose rate gemcitabine (gem) in patients with advanced cancer. Proc Am Soc Clin Onc. 24:2049 (abstract #), 2006.
64. Lan F, Ballard H, Chen A, Leung R, **Chachoua A**, Taneja S, Ferrari A. Phase I/II study of sequential-intermittent docetaxel (D) and imatinib (Im) in hormone refractory prostate cancer (HRPC) (NYU 04-47). Proc Am Soc Clin Onc. 25:15613, 2007.